Sotera Health (SHC) concentration risks

The company's disclosed concentration profile is entirely on the supply side, with two critical inputs each sourced from highly concentrated provider bases. The sharpest exposure is the U.S. ethylene oxide supply chain: there is a single supplier for EO in the United States for the sterilization business, a high-share dependency. Ethylene oxide is the primary sterilant for the business, and having a sole domestic source means any supplier disruption — a plant outage, regulatory action, force majeure event, or contract failure — would directly impair sterilization capacity with no immediate domestic alternative available. The second exposure is the cobalt-60 supply chain. Approximately 20% of the long-term supply of Co-60 is estimated to come from Russian nuclear reactors, a moderate-share dependency, and the filing discloses that this share may increase to as much as approximately 50%. Cobalt-60 is used in radiation sterilization and is produced as a byproduct of nuclear reactor operations; the geopolitical and sanctions-related risks associated with Russian-sourced material add an idiosyncratic country-level dimension that could limit access independent of commercial factors. Together, the EO and Co-60 dependencies cover both major sterilization modalities the company operates. Because neither can be quickly substituted, a supply disruption in either would have direct consequences for sterilization throughput and customer delivery commitments. The EO single-supplier exposure is the more immediately actionable risk; the Russian reactor dependency is the longer-term structural concern as that share could grow.

For the engine’s reasoning on SHC’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.